Into Kirin: giving up independence to focus on drugs (2007)

The scale won by surrendering independence, and the weight of a parent

The heart of this decision is that a diversified fermentation company gave up its independence and, under the capital of the Kirin group, gained the scale to concentrate on pharmaceuticals. It was not a hostile takeover but a consensual combination, one for which President Matsuda showed strong internal support, and the stated rationale — the complementarity of the two companies’ fermentation technology — had a fair logic to it. The focus on antibody drugs, a growth field, was borne out by the expansion of sales and profit that followed. The combination did indeed deliver a scale of research and development that Kyowa Hakko could never have reached alone.

Yet a parent-subsidiary listing, crowned by a parent holding 50.10% of the voting rights, left in place a structure that bends the later business portfolio to the parent’s convenience. Both the spin-off of the non-pharmaceutical businesses in 2011 and the transfer of the high-earning Kyowa Hakko Bio to its parent, Kirin Holdings, in 2019 trace back to this 2008 capital combination. Autonomy as an independent company, or the scale that group capital brings — which to take? Kyowa Hakko’s choice stands as one worked example of exactly what such an exchange gains, and what it gives up.